FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963598564> ?p ?o ?g. }

• W1963598564 abstract "Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells at multiple sites in the bone marrow, with accompanying alterations in the bone marrow microenvironment, and suppression of the host antitumor immune response, resulting in the uncontrolled accumulation of malignant plasma cells and excess secretion of immunoglobulins (paraproteins). MM, in almost all cases, is preceded by a premalignant phase, monoclonal gammopathy of undetermined significance (MGUS).1 MGUS is present in ∼3% of the population aged >50 years and progresses through asymptomatic smoldering myeloma to symptomatic MM at a rate of 1% annually.2 MM is usually diagnosed when the disease becomes symptomatic, classically presenting with bone pain, anemia, renal insufficiency, hypercalcemia and recurrent infections due to immune deficiency. MM has an annual age-adjusted incidence of 5.8 cases per 100 000 of the population and predominantly affects older individuals; the median age at diagnosis is 69 years.3, 4MM is an incurable disease and the survival prognosis for patients diagnosed with MM has historically been poor. The introduction of high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) in the 1980s improved response rates and progression-free survival (PFS), but median overall survival (OS) remained at 65 years for whom OS is only 26 months.8 The treatment of MM in elderly patients remains a clinical challenge—they are usually ineligible for stem cell transplantation and are unable to tolerate the toxicity of intense chemotherapy. Besides age at diagnosis and disease stage, prognosis is also adversely affected by the presence of several ‘high-risk' genetic markers, including deletions of chromosome 13, hypodiploidy and deletions of chromosome 17p, t(4;14) or t(14;16).2Significant improvements in response rates, PFS and OS have been seen in patients with NDMM treated with combination regimens based on immunomodulatory drugs (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib).9, 10, 11, 12, 13, 14, 15, 16 These advances, coupled with an improved understanding of the disease, have shifted the treatment paradigm in MM. The current aim of this therapy for patients with NDMM is to achieve deep and long-term clinical remissions with early and continued use of regimens that are effective and safe to maintain disease control and extend OS.The purpose of this supplement is to review current approaches to the treatment of NDMM, providing an update on the most recent developments and treatment regimens involving the novel therapies, and highlighting the key issues that clinicians face when devising a long-term management strategy for NDMM patients. In the first article, Drs Munshi and Girnius provide an overview of the current approaches related to the diagnosis and management of MGUS, smoldering MM and MM, highlighting the need for a long-term approach to optimize disease control and the importance of a risk-stratified approach to treatment. In the second article, Drs Giralt and Bensinger discuss the role of ASCT and the role of novel therapies in induction treatment. The question of how to optimize the response to ASCT using consolidation therapy with novel agents is then addressed by Drs Moreau and Touzeau, including a review of recent clinical evidence showing the benefit of post-transplantation maintenance treatment with novel agents to extend PFS. Finally, Professor San Miguel and Dr Mateos provide an overview of the treatment options available for NDMM patients ineligible for HDT–ASCT because of either advanced age or comorbid conditions. Again, the focus is on the way in which the novel therapies have transformed the treatment options available to this population, who represent the majority of NDMM patients. In this setting, early and continued treatment with novel agents appears to have the potential to extend survival times for elderly and frail patients for whom outcomes have remained poor.Collectively, these articles illustrate how the introduction of novel agents, such as lenalidomide and bortezomib, has transformed the approach to treatment of NDMM and has provided a valuable clinical update for those working in this field." @default.
• W1963598564 created "2016-06-24" @default.
• W1963598564 creator A5023276777 @default.
• W1963598564 date "2013-05-01" @default.
• W1963598564 modified "2023-09-23" @default.
• W1963598564 title "Advances in current treatment for patients with newly diagnosed multiple myeloma" @default.
• W1963598564 cites W1801543025 @default.
• W1963598564 cites W1965249739 @default.
• W1963598564 cites W1969648097 @default.
• W1963598564 cites W2031157863 @default.
• W1963598564 cites W2055338149 @default.
• W1963598564 cites W2066800926 @default.
• W1963598564 cites W2113604545 @default.
• W1963598564 cites W2132392953 @default.
• W1963598564 cites W2151595053 @default.
• W1963598564 cites W2160088903 @default.
• W1963598564 cites W2168018375 @default.
• W1963598564 cites W2169336006 @default.
• W1963598564 cites W2341609337 @default.
• W1963598564 cites W2474872853 @default.
• W1963598564 cites W2558404559 @default.
• W1963598564 doi "https://doi.org/10.1038/leusup.2013.1" @default.
• W1963598564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4851185" @default.
• W1963598564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27175254" @default.
• W1963598564 hasPublicationYear "2013" @default.
• W1963598564 type Work @default.
• W1963598564 sameAs 1963598564 @default.
• W1963598564 citedByCount "1" @default.
• W1963598564 countsByYear W19635985642014 @default.
• W1963598564 crossrefType "journal-article" @default.
• W1963598564 hasAuthorship W1963598564A5023276777 @default.
• W1963598564 hasBestOaLocation W19635985641 @default.
• W1963598564 hasConcept C126322002 @default.
• W1963598564 hasConcept C143998085 @default.
• W1963598564 hasConcept C159654299 @default.
• W1963598564 hasConcept C163864487 @default.
• W1963598564 hasConcept C203014093 @default.
• W1963598564 hasConcept C2776364478 @default.
• W1963598564 hasConcept C2777250017 @default.
• W1963598564 hasConcept C2777910003 @default.
• W1963598564 hasConcept C2779050716 @default.
• W1963598564 hasConcept C2780007613 @default.
• W1963598564 hasConcept C2908647359 @default.
• W1963598564 hasConcept C2911091166 @default.
• W1963598564 hasConcept C542903549 @default.
• W1963598564 hasConcept C71924100 @default.
• W1963598564 hasConcept C90924648 @default.
• W1963598564 hasConcept C99454951 @default.
• W1963598564 hasConceptScore W1963598564C126322002 @default.
• W1963598564 hasConceptScore W1963598564C143998085 @default.
• W1963598564 hasConceptScore W1963598564C159654299 @default.
• W1963598564 hasConceptScore W1963598564C163864487 @default.
• W1963598564 hasConceptScore W1963598564C203014093 @default.
• W1963598564 hasConceptScore W1963598564C2776364478 @default.
• W1963598564 hasConceptScore W1963598564C2777250017 @default.
• W1963598564 hasConceptScore W1963598564C2777910003 @default.
• W1963598564 hasConceptScore W1963598564C2779050716 @default.
• W1963598564 hasConceptScore W1963598564C2780007613 @default.
• W1963598564 hasConceptScore W1963598564C2908647359 @default.
• W1963598564 hasConceptScore W1963598564C2911091166 @default.
• W1963598564 hasConceptScore W1963598564C542903549 @default.
• W1963598564 hasConceptScore W1963598564C71924100 @default.
• W1963598564 hasConceptScore W1963598564C90924648 @default.
• W1963598564 hasConceptScore W1963598564C99454951 @default.
• W1963598564 hasLocation W19635985641 @default.
• W1963598564 hasLocation W19635985642 @default.
• W1963598564 hasLocation W19635985643 @default.
• W1963598564 hasLocation W19635985644 @default.
• W1963598564 hasOpenAccess W1963598564 @default.
• W1963598564 hasPrimaryLocation W19635985641 @default.
• W1963598564 hasRelatedWork W111334434 @default.
• W1963598564 hasRelatedWork W2047345996 @default.
• W1963598564 hasRelatedWork W2413642622 @default.
• W1963598564 hasRelatedWork W2435227317 @default.
• W1963598564 hasRelatedWork W2524976195 @default.
• W1963598564 hasRelatedWork W2529376761 @default.
• W1963598564 hasRelatedWork W2794786052 @default.
• W1963598564 hasRelatedWork W2802828592 @default.
• W1963598564 hasRelatedWork W3094341023 @default.
• W1963598564 hasRelatedWork W3198647362 @default.
• W1963598564 isParatext "false" @default.
• W1963598564 isRetracted "false" @default.
• W1963598564 magId "1963598564" @default.
• W1963598564 workType "article" @default.